[1] |
LABLANCHE S, BOROT S, WOJTUSCISZYN A, et al. Ten-year outcomes of islet transplantation in patients with type 1 diabetes: data from the Swiss-French GRAGIL network[J]. Am J Transplant, 2021, 21(11): 3725-3733. DOI: 10.1111/ajt.16637.
|
[2] |
MARKMANN JF, RICKELS MR, EGGERMAN TL, et al. Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes[J]. Am J Transplant, 2021, 21(4): 1477-1492. DOI: 10.1111/ajt.16174.
|
[3] |
FOSTER ED, BRIDGES ND, FEURER ID, et al. Improved health-related quality of life in a phase 3 islet transplantation trial in type 1 diabetes complicated by severe hypoglycemia[J]. Diabetes Care, 2018, 41(5): 1001-1008. DOI: 10.2337/dc17-1779.
|
[4] |
中华医学会器官移植学分会. 胰岛移植临床技术操作规范(2019版)[J]. 器官移植, 2019, 10(6): 621-627. DOI: 10.3969/j.issn.1674-7445.2019.06.001.Branch of Organ Transplantation of Chinese Medical Association. Clinical technical operation specification of pancreatic islet transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(6): 621-627. DOI: 10.3969/j.issn.1674-7445.2019.06.001.
|
[5] |
SAMY KP, DAVIS RP, GAO Q, et al. Early barriers to neonatal porcine islet engraftment in a dual transplant model[J]. Am J Transplant, 2018, 18(4): 998-1006. DOI: 10.1111/ajt.14601.
|
[6] |
ERIKSSON O, SELVARAJU R, EICH T, et al. Positron emission tomography to assess the outcome of intraportal islet transplantation[J]. Diabetes, 2016, 65(9): 2482-2489. DOI: 10.2337/db16-0222.
|
[7] |
HU M, HAWTHORNE WJ, YI S, et al. Cellular immune responses in islet xenograft rejection[J]. Front Immunol, 2022, 13: 893985. DOI: 10.3389/fimmu.2022.893985.
|
[8] |
NAZIRUDDIN B, IWAHASHI S, KANAK MA, et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation[J]. Am J Transplant, 2014, 14(2): 428-437. DOI: 10.1111/ajt.12558.
|
[9] |
MIYAGAWA S, MAEDA A, TOYAMA C, et al. Aspects of the complement system in new era of xenotransplantation[J]. Front Immunol, 2022, 13: 860165. DOI: 10.3389/fimmu.2022.860165.
|
[10] |
YAO M, DOMOGATSKAYA A, ÅGREN N, et al. Cibinetide protects isolated human islets in a stressful environment and improves engraftment in the perspective of intra portal islet transplantation[J]. Cell Transplant, 2021, 30: 9636897211039739. DOI: 10.1177/09636897211039739.
|
[11] |
BACHUL PJ, GOLAB K, BASTO L, et al. Post-hoc analysis of a randomized, double blind, prospective study at the University of Chicago: additional standardizations of trial protocol are needed to evaluate the effect of a CXCR1/2 inhibitor in islet allotransplantation[J]. Cell Transplant, 2021, 30: 9636897211001774. DOI: 10.1177/09636897211001774.
|
[12] |
MAFFI P, LUNDGREN T, TUFVESON G, et al. Targeting CXCR1/2 does not improve insulin secretion after pancreatic islet transplantation: a phase 3, double-blind, randomized, placebo-controlled trial in type 1 diabetes[J]. Diabetes Care, 2020, 43(4): 710-718. DOI: 10.2337/dc19-1480.
|
[13] |
GUSTAFSON E, ASIF S, KOZARCANIN H, et al. Control of IBMIR induced by fresh and cryopreserved hepatocytes by low molecular weight dextran sulfate versus heparin[J]. Cell Transplant, 2017, 26(1): 71-81. DOI: 10.3727/096368916X692609.
|
[14] |
SHI Y, ZHAO YZ, JIANG Z, et al. Immune-protective formulations and process strategies for improved survival and function of transplanted islets[J]. Front Immunol, 2022, 13: 923241. DOI: 10.3389/fimmu.2022.923241.
|
[15] |
VON ZUR-MÜHLEN B, LUNDGREN T, BAYMAN L, et al. Open randomized multicenter study to evaluate safety and efficacy of low molecular weight sulfated dextran in islet transplantation[J]. Transplantation, 2019, 103(3): 630-637. DOI: 10.1097/TP.0000000000002425.
|
[16] |
PARK SS, RODRIGUEZ ORTEGA R, AGUDELO CW, et al. Therapeutic potential of alpha-1 antitrypsin in type 1 and type 2 diabetes mellitus[J]. Medicina (Kaunas), 2021, 57(4): 397. DOI: 10.3390/medicina57040397.
|
[17] |
WANG J, SUN Z, GOU W, et al. α-1 antitrypsin enhances islet engraftment by suppression of instant blood-mediated inflammatory reaction[J]. Diabetes, 2017, 66(4): 970-980. DOI: 10.2337/db16-1036.
|
[18] |
GOU W, WANG J, SONG L, et al. Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation[J]. Am J Transplant, 2021, 21(5): 1713-1724. DOI: 10.1111/ajt.16342.
|
[19] |
LAGARDE WH, COURTNEY KL, REINER B, et al. Human plasma-derived alph 1-proteinase inhibitor in patients with new-onset type 1 diabetes mellitus: a randomized, placebo-controlled proof-of-concept study[J]. Pediatr Diabetes, 2021, 22(2): 192-201. DOI: 10.1111/pedi.13162.
|
[20] |
ZHANG Q, GONELLE-GISPERT C, LI Y, et al. Islet encapsulation: new developments for the treatment of type 1 diabetes[J]. Front Immunol, 2022, 13: 869984. DOI: 10.3389/fimmu.2022.869984.
|
[21] |
PIGNATELLI C, CAMPO F, NERONI A, et al. Bioengineering the vascularized endocrine pancreas: a fine-tuned interplay between vascularization, extracellular-matrix-based scaffold architecture, and insulin-producing cells[J]. Transpl Int, 2022, 35: 10555. DOI: 10.3389/ti.2022.10555.
|
[22] |
PARK H, HAQUE MR, PARK JB, et al. Polymeric nano-shielded islets with heparin-polyethylene glycol in a non-human primate model[J]. Biomaterials, 2018, 171: 164-177. DOI: 10.1016/j.biomaterials.2018.04.028.
|
[23] |
WANG W, TENG Y, XUE JJ, et al. Nanotechnology in kidney and islet transplantation: an ongoing, promising field[J]. Front Immunol, 2022, 13: 846032. DOI: 10.3389/fimmu.2022.846032.
|
[24] |
BUITINGA M, JANECZEK PORTALSKA K, CORNELISSEN DJ, et al. Coculturing human islets with proangiogenic support cells to improve islet revascularization at the subcutaneous transplantation site[J]. Tissue Eng Part A, 2016, 22(3/4): 375-385. DOI: 10.1089/ten.tea.2015.0317.
|
[25] |
JUNG HS, KIM MJ, HONG SH, et al. The potential of endothelial colony-forming cells to improve early graft loss after intraportal islet transplantation[J]. Cell Transplant, 2014, 23(3): 273-283. DOI: 10.3727/096368912X661364.
|
[26] |
DE KLERK E, HEBROK M. Stem cell-based clinical trials for diabetes mellitus[J]. Front Endocrinol (Lausanne), 2021, 12: 631463. DOI: 10.3389/fendo.2021.631463.
|
[27] |
MOCHIZUKI Y, KOGAWA R, TAKEGAMI R, et al. Co-microencapsulation of islets and MSC cellsaics, mosaic-like aggregates of MSCs and recombinant peptide pieces, and therapeutic effects of their subcutaneous transplantation on diabetes[J]. Biomedicines, 2020, 8(9): 318. DOI: 10.3390/biomedicines8090318.
|
[28] |
KOURTZELIS I, KOTLABOVA K, LIM JH, et al. Developmental endothelial locus-1 modulates platelet-monocyte interactions and instant blood-mediated inflammatory reaction in islet transplantation[J]. Thromb Haemost, 2016, 115(4): 781-788. DOI: 10.1160/TH15-05-0429.
|
[29] |
KOGAWA R, NAKAMURA K, MOCHIZUKI Y. A new islet transplantation method combining mesenchymal stem cells with recombinant peptide pieces, microencapsulated islets, and mesh bags[J]. Biomedicines, 2020, 8(9): 299. DOI: 10.3390/biomedicines8090299.
|
[30] |
KUMANO K, KANAK MA, SARAVANAN PB, et al. Withaferin A inhibits lymphocyte proliferation, dendritic cell maturation in vitro and prolongs islet allograft survival[J]. Sci Rep, 2021, 11(1): 10661. DOI: 10.1038/s41598-021-90181-y.
|
[31] |
GLEIZES C, CONSTANTINESCU A, ABBAS M, et al. Liraglutide protects Rin-m5f β cells by reducing procoagulant tissue factor activity and apoptosis prompted by microparticles under conditions mimicking instant blood-mediated inflammatory reaction[J]. Transpl Int, 2014, 27(7): 733-740. DOI: 10.1111/tri.12286.
|
[32] |
CAYABYAB F, NIH LR, YOSHIHARA E. Advances in pancreatic islet transplantation sites for the treatment of diabetes[J]. Front Endocrinol (Lausanne), 2021, 12: 732431. DOI: 10.3389/fendo.2021.732431.
|
[33] |
POISSON J, LEMOINNE S, BOULANGER C, et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases[J]. J Hepatol, 2017, 66(1): 212-227. DOI: 10.1016/j.jhep.2016.07.009.
|
[34] |
YAN LL, YE LP, CHEN YH, et al. The influence of microenvironment on survival of intraportal transplanted islets[J]. Front Immunol, 2022, 13: 849580. DOI: 10.3389/fimmu.2022.849580.
|
[35] |
DAMYAR K, FARAHMAND V, WHALEY D, et al. An overview of current advancements in pancreatic islet transplantation into the omentum[J]. Islets, 2021, 13(5/6): 115-120. DOI: 10.1080/19382014.2021.1954459.
|
[36] |
MCQUILLING JP, SITTADJODY S, PARETA R, et al. Retrieval of microencapsulated islet grafts for post-transplant evaluation[J]. Methods Mol Biol, 2017, 1479: 157-171. DOI: 10.1007/978-1-4939-6364-5_12.
|
[37] |
BAIDAL DA, RICORDI C, BERMAN DM, et al. Bioengineering of an intraabdominal endocrine pancreas[J]. N Engl J Med, 2017, 376(19): 1887-1889. DOI: 10.1056/NEJMc1613959.
|
[38] |
LEI J, CORONEL MM, YOLCU ES, et al. FasL microgels induce immune acceptance of islet allografts in nonhuman primates[J]. Sci Adv, 2022, 8(19): eabm9881. DOI: 10.1126/sciadv.abm9881.
|
[39] |
LEI J, ZHANG A, DENG H, et al. Intrapleural transplantation of allogeneic pancreatic islets achieves glycemic control in a diabetic non-human primate[J]. Am J Transplant, 2022, 22(3): 966-972. DOI: 10.1111/ajt.16875.
|
[40] |
LAU H, KHOSRAWIPOUR T, ALEXANDER M, et al. Islet transplantation in the lung via endoscopic aerosolization: investigation of feasibility, islet cluster cell vitality, and structural integrity[J]. Cell Transplant, 2020, 29: 963689720949244. DOI: 10.1177/0963689720949244.
|